American Coastal (ACIC) Upgraded to Buy: Here's What You Should Know — Positive
ACIC Zacks Investment Research — November 19, 2025American Coastal (ACIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are You Looking for a Top Momentum Pick? Why Hecla Mining (HL) is a Great Choice — Positive
HL Zacks Investment Research — November 19, 2025Does Hecla Mining (HL) have what it takes to be a top stock pick for momentum investors? Let's find out.
HomeTrust Bancshares (HTB) Upgraded to Buy: Here's What You Should Know — Positive
HTB Zacks Investment Research — November 19, 2025HomeTrust Bancshares (HTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Profound Medical (PROF) Upgraded to Buy: What Does It Mean for the Stock? — Positive
PROF Zacks Investment Research — November 19, 2025Profound Medical (PROF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch (BHC) Upgraded to Buy: Here's Why — Positive
BHC Zacks Investment Research — November 19, 2025Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sony (SONY) Upgraded to Strong Buy: What Does It Mean for the Stock? — Positive
SONY Zacks Investment Research — November 19, 2025Sony (SONY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Ameriprise (AMP) Upgraded to Buy: What Does It Mean for the Stock? — Positive
AMP Zacks Investment Research — November 19, 2025Ameriprise (AMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy — Positive
ONCY Zacks Investment Research — November 19, 2025Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
QQQ vs. VTI: One Clear Winner for Building Long Term Wealth — Neutral
QQQ VTI 24/7 Wall Street — November 19, 2025In most years, especially in strong up years, the Nasdaq 100 has stood taller than the S&P 500, driven largely by the tech sector's outsized gains. Invesco's Q3 update shows QQQ with a NAV gain of 8.94 percent in Q3 2025, edging out the S&P 500's 8.12 percent. Still, outperformance on the way up does not guarantee the same result going forward, particularly if tech shifts from boom to sudden slowdown.
HUMAIN AND ADOBE ANNOUNCE GLOBAL STRATEGIC PARTNERSHIP TO BUILD AI MODELS AND AI-POWERED APPLICATIONS TUNED FOR THE ARAB WORLD AT THE U.S.-SAUDI INVESTMENT FORUM — Neutral
ADBE PRNewsWire — November 19, 2025A first-of-its-kind collaboration across models, applications, agents, and infrastructure, Adobe and HUMAIN's partnership marks the start of a deep collaboration across HUMAIN Cloud, HUMAIN ONE, ALLAM, Adobe Creative Cloud, Express, Firefly, Acrobat, and Adobe's digital marketing products. HUMAIN will be a strategic technology partner for Adobe Firefly Foundry, allowing companies to develop culturally aware models trained on their content, and will empower over 400 million Arabic speakers globally with the most advanced generative AI for the Arab world.
Cisco Up 35% in a Year: Is There More Room for the Stock to Rise? — Positive
CSCO Zacks Investment Research — November 19, 2025CSCO's AI-fueled order surge, new products and upbeat 2026 outlook lift momentum, even as valuation risks keep the stock in focus.
Deadline Alert: Molina Healthcare, Inc. (MOH) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit — Neutral
MOH GlobeNewsWire — November 19, 2025LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 2, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) securities between February 5, 2025 and July 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR MOLINA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons — Neutral
GMAB GlobeNewsWire — November 19, 2025Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
JetBlue to add Milan, Barcelona flights next year in push for high-spending travelers — Positive
JBLU CNBC — November 19, 2025JetBlue Airways is adding seasonal flights to Barcelona and Milan from Boston next spring. The new flights show how JetBlue is pushing its Airbus 321 narrow-body planes deeper into Europe.
Algorhythm Holdings Q3 Revenues Surge 1273%, From About Zero to $1.7 Million — Neutral
RIME Accesswire — November 19, 2025FORT LAUDERDALE, FL / ACCESS Newswire / November 19, 2025 / When a company reports a 1,273% year-over-year revenue jump, the number naturally captures attention. In Algorhythm Holdings' (NASDAQ:RIME) case, the most important insight is not only the size of the increase.
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit — Neutral
MLTX GlobeNewsWire — November 19, 2025LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
The Western Union Company (WU) Presents at Citi's 14th Annual FinTech Conference Transcript — Neutral
WU Seeking Alpha — November 19, 2025The Western Union Company ( WU ) Citi's 14th Annual FinTech Conference November 19, 2025 9:45 AM EST Company Participants Devin McGranahan - President, CEO & Director Conference Call Participants Bryan Keane - Citigroup Inc., Research Division Presentation Bryan Keane Citigroup Inc., Research Division Okay. Welcome. We're excited to have Western Union here.
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript — Neutral
ICCM Seeking Alpha — November 19, 2025IceCure Medical Ltd ( ICCM ) Q3 2025 Earnings Call November 19, 2025 10:00 AM EST Company Participants Eyal Shamir - CEO & Director Ronen Tsimerman - Chief Financial Officer Conference Call Participants Michael Polyviou - EVC Group Inc. Anthony Vendetti - Maxim Group LLC, Research Division Presentation Operator Good morning, and thank you for standing by. [Operator Instructions] Please be advised that today's conference call is being recorded.
Securities Fraud Investigation Into Zimmer Biomet Holdings, Inc. (ZBH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm — Neutral
ZBH GlobeNewsWire — November 19, 2025LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Zimmer Biomet Holdings, Inc. (“Zimmer” or the “Company”) (NYSE: ZBH) investors concerning the Company's possible violations of the federal securities laws.
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing — Neutral
TLX PRNewsWire — November 19, 2025PHILADELPHIA , Nov. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").